PHXM
PHAXIAM Therapeutics S.A.
NASDAQ: PHXM · HEALTHCARE · BIOTECHNOLOGY
$3.10
+0.00% today
Updated 2026-05-01
Market cap
$28.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-39.05
Dividend yield
—
52W range
$0 – $0
Volume
—
PHAXIAM Therapeutics S.A. (PHXM) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-5.34M | $-5.08M | $621402.00 | $-6.47M | $-7.24M | $-14.58M | $-17.61M | $-24.70M | $-39.27M | $-43.31M | $-51.72M | $-56.77M | $-31.76M | $-24.37M |
| Capital expenditures | $183043.00 | $92465.00 | $52502.00 | $427399.00 | $421439.00 | $269000.00 | $1.75M | $1.69M | $14.22M | $20.13M | $1.14M | $298000.00 | $85000.00 | $217000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | $66266.00 | $580621.00 | $1.24M | $2.72M | $1.18M | $1.77M | $2.45M | $1.36M | $1.18M | $1.32M | $447000.00 | — |
| Free cash flow | $-5.52M | $-5.17M | $568900.00 | $-6.90M | $-7.66M | $-14.85M | $-19.36M | $-26.39M | $-53.49M | $-63.44M | $-52.86M | $-57.07M | $-31.85M | $-24.58M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $791236.00 | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — |